Veracyte, Inc. (VCYT) Stock Price & How to Invest

Veracyte is a US genomic diagnostics company that develops and runs advanced molecular tests used to guide cancer treatment decisions. Its two flagship products drive the business: Decipher, a genomic classifier for prostate cancer, and Afirma, which helps assess indeterminate thyroid nodules to avoid unnecessary surgeries. The company also markets other tests, including Prosigna, a breast cancer risk-of-recurrence test that launched in the US in June 2026 and gained Medicare coverage through the MolDX program effective August 19, 2026, and it runs a research platform (Afirma GRID, Decipher studies) built on large proprietary genomic sample databases that give it a competitive moat. Testing revenue is the dominant and fastest-growing part of the mix.

The investment picture is one of a diagnostics company that has crossed into sustained profitability, a relative rarity in the space. Q1 2026 revenue rose roughly 21% year over year to about $139M, and Q2 2026 revenue rose about 15.5% to roughly $150M with GAAP net income of about $25M; adjusted EPS of $0.54 beat the ~$0.43 consensus, the fourth straight beat. Trailing revenue is about $562M with ~$114M of net income, ~74% gross margins, ~$106M of free cash flow, and about $485M of cash against ~$40M of debt. The stock has been volatile: it fell about 26% over the three months to mid-October 2026 from a 52-week high near $61, leaving it up ~4% year to date and ~23% over one year. At about $44 it trades near 31x trailing and 23x forward earnings with a market value around $3.5B, still a premium, so the concentration in two tests plus reimbursement dependence are the key things to weigh.

Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. Growth slowed from about 21% in Q1 2026 to about 15.5% in Q2, and analysts expect only ~2% EPS growth in 2027, so the valuation (about 31x trailing and 23x forward earnings) still amplifies downside if growth decelerates further; the shares already fell ~26% in the three months to mid-October 2026. Medicare and commercial payer decisions drive a large portion of realized revenue, making pricing and coverage a persistent uncertainty. Larger diagnostics rivals such as Exact Sciences, Guardant Health, and Natera have deeper resources and are expanding into overlapping oncology testing areas. New-test launches such as Prosigna and international expansion carry execution and regulatory risk.

12 analysts publish price targets on VCYT, averaging $58.42 against a $43.12 price as of October 2026, or +35.5%. The published targets run from $44.00 to $70.00, a moderate spread, and the ratings split 11 buy, 1 hold, 1 sell. Over the last six months there have been 5 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VCYT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Veracyte, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Decipher prostate franchise. Decipher is the largest and fastest-growing revenue line, up roughly 30% year over year in Q1 2026 to about $87M in testing revenue. The most optimistic published target, $70.00, assumes this works close to its best case.

The case against. Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The most pessimistic target, $44.00, is roughly what VCYT is worth if this bites instead.

Read the full bull and bear case on VCYT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Veracyte, Inc. (VCYT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Veracyte, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$562M
• Q2 2026 revenue: ~$150M (up ~15.5% YoY)
• Net income (TTM): ~$114M
• Gross / operating margin: ~74% / ~15%
• P/E (trailing / forward): ~31x / ~23x
• Market cap: ~$3.5B
• Cash vs debt: ~$485M vs ~$40M

Veracyte is profitable on a GAAP basis with ~74% gross margins and positive free cash flow, an uncommon profile among growth-stage diagnostics firms. After the summer pullback the multiple has compressed to about 31x trailing and 23x forward earnings, still above many diagnostics peers and priced for continued double-digit testing growth. Q3 2026 results are due November 4, 2026, with consensus near $0.41 of EPS on ~$147M of revenue; figures are approximate as of October 16, 2026.

Other names that sit close to VCYT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VCYT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VCYT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VCYT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

VCYT is a rare profitable, cash-generative diagnostics name with ~$485M of cash; its multiple has compressed to ~31x trailing and ~23x forward earnings after a sharp summer pullback, but it still leaves little room for a growth stumble in its two core tests. Q3 results are due November 4, 2026.

Whether VCYT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VCYT a buy or a sell?, and where the stock could go from here in the VCYT stock forecast.

For income investors, whether VCYT pays a dividend and how the payout looks is covered in does VCYT pay a dividend? And to weigh VCYT against a peer, read the full side-by-side comparisons: VCYT vs GH and VCYT vs GRAL.